Physician profile
Ted J Ryser
NPI 1326434069
$4,812.96
in general payments reported to CMS, 2019-2025
21 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $161 · 2021: $482 · 2022: $637 · 2023: $908 · 2024: $1,200 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,110 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,109.54 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,726.08 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $634.52 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $277.06 | 2020-2025 | Nemluvio, Aklief |
| Ucb, INC. | $269.03 | 2020-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $267.46 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $195.37 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $181.50 | 2019-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $167.42 | 2019-2024 | Dupixent |
| Dermavant Sciences, INC. | $153.22 | 2023-2024 | Vtama |
| Lilly USA, LLC | $145.25 | 2019-2024 | Olumiant, Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $133.98 | 2023-2024 | Zoryve |
| Incyte Corporation | $133.21 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $132.58 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $125.36 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.72 | 2024 | Spevigo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $71.53 | 2021 | |
| Amgen INC. | $44.64 | 2022-2025 | Otezla |
| Helsinn Therapeutics (U.S.), INC. | $27.77 | 2022 | |
| Organon LLC | $17.86 | 2025 | Vtama |
| Kyowa Kirin, INC. | $12.90 | 2021 | |
| Pfizer INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Ryser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.